Category | 2014 n (%) | 2015 n (%) | 2016 n (%) | 2017 n (%) | 2018 n (%) | 2019 n (%) | Total n (%) | χ2 | P |
---|---|---|---|---|---|---|---|---|---|
All TB cases | |||||||||
 Any drug-resistance | 95 (42.6) | 85 (49.7) | 60 (56.1) | 96 (50.5) | 127 (38.4) | 195 (42.2) | 658 (44.3) | 16.820 | 0.005 |
 INH | 71 (31.8) | 67 (39.2) | 42 (39.3) | 68 (35.8) | 85 (25.7) | 132 (28.6) | 465 (31.3) | 16.349 | 0.006 |
 RIF | 60 (26.9) | 63 (36.8) | 48 (44.9) | 68 (35.8) | 86 (26.0) | 136 (29.4) | 461 (31.1) | 20.521 | 0.001 |
 EMB | 23 (10.3) | 12 (7.0) | 20 (18.7) | 26 (13.7) | 26 (7.9) | 41 (8.9) | 148 (10.0) | 15.941 | 0.007 |
 STR | 48 (21.5) | 39 (22.8) | 24 (22.4) | 50 (26.3) | 56 (16.9) | 98 (21.2) | 315 (21.2) | 6.977 | 0.222 |
 MDR | 54 (24.2) | 50 (29.2) | 38 (35.5) | 53 (27.9) | 63 (19.0) | 111 (24.0) | 369 (24.9) | 15.430 | 0.009 |
 Any second-line drug resistance | 42 (18.8) | 43 (25.1) | 34 (31.8) | 46 (24.2) | 47 (14.2) | 96 (20.8) | 308 (20.8) | 20.435 | 0.001 |
 CPM | 2 (0.9) | 3 (1.8) | 3 (2.8) | 7 (3.7) | 6 (1.8) | 21 (4.5) | 42 (2.8) | 10.443 | 0.064 |
 KAR | 6 (2.7) | 5 (2.9) | 7 (6.5) | 13 (6.8) | 6 (1.8) | 14 (3.0) | 51 (3.4) | 13.119 | 0.022 |
 OFX | 38 (17.0) | 41 (24.0) | 33 (30.8) | 42 (22.1) | 43 (13.0) | 76 (16.5) | 273 (18.4) | 24.208 | < 0.001 |
 PTO | 1 (0.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 18 (3.9) | 20 (1.3) | 34.796 | < 0.001 |
 XDR | 4 (1.8) | 3 (1.8) | 5 (4.7) | 10 (5.3) | 4 (1.2) | 7 (1.5) | 33 (2.2) | 11.580 | 0.041 |
New cases | |||||||||
 Any drug-resistance | 35 (28.0) | 22 (25.0) | 13 (33.3) | 29 (30.9) | 47 (24.0) | 67 (23.7) | 213 (25.8) | 3.759 | 0.585 |
 INH | 22 (17.6) | 14 (15.9) | 6 (15.4) | 17 (18.1) | 27 (13.8) | 36 (12.7) | 122 (14.8) | 2.813 | 0.729 |
 RIF | 15 (12.0) | 8 (9.1) | 7 (17.9) | 13 (13.8) | 23 (11.7) | 28 (9.9) | 94 (11.4) | 3.181 | 0.672 |
 EMB | 6 (4.8) | 2 (2.3) | 1 (2.6) | 4 (4.3) | 6 (3.1) | 11 (3.9) | 30 (3.6) | 1.462 | 0.917 |
 STR | 17 (13.6) | 9 (10.2) | 6 (15.4) | 13 (13.8) | 25 (12.8) | 31 (11.0) | 101 (12.2) | 1.604 | 0.901 |
 MDR | 14 (11.2) | 4 (4.5) | 5 (12.8) | 8 (8.5) | 15 (7.7) | 25 (8.8) | 71 (8.6) | 4.210 | 0.520 |
 Any second-line drug resistance | 13 (10.4) | 7 (8.0) | 7 (17.9) | 11 (11.7) | 12 (6.1) | 26 (9.2) | 76 (9.2) | 6.397 | 0.270 |
 CPM | 1 (0.8) | 1 (1.1) | 0 (0.0) | 3 (3.2) | 3 (1.5) | 7 (2.5) | 15 (1.8) | 4.133 | 0.530 |
 KAR | 2 (1.6) | 1 (1.1) | 0 (0.0) | 4 (4.3) | 1 (0.5) | 6 (2.1) | 14 (1.7) | 6.696 | 0.244 |
 OFX | 10 (8.0) | 7 (8.0) | 7 (17.9) | 8 (8.5) | 10 (5.1) | 17 (6.0) | 59 (7.2) | 7.388 | 0.193 |
 PTO | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.7) | 2 (0.2) | 4.289 | 0.509 |
 XDR | 0 (0.0) | 1 (1.1) | 0 (0.0) | 1 (1.1) | 0 (0.0) | 1 (0.4) | 3 (0.4) | 4.383 | 0.496 |
Retreatment cases | |||||||||
 Any drug-resistance | 60 (61.2) | 63 (75.9) | 47 (69.1) | 67 (69.8) | 80 (59.3) | 128 (71.5) | 445 (67.5) | 10.236 | 0.069 |
 INH | 49 (50.0) | 53 (63.9) | 36 (52.9) | 51 (53.1) | 58 (43.0) | 96 (53.6) | 343 (52.0) | 9.512 | 0.090 |
 RIF | 45 (45.9) | 55 (66.3) | 41 (60.3) | 55 (57.3) | 63 (46.7) | 108 (60.3) | 367 (55.7) | 14.257 | 0.014 |
 EMB | 17 (17.3) | 10 (12.0) | 19 (27.9) | 22 (22.9) | 20 (14.8) | 30 (16.8) | 118 (17.9) | 9.294 | 0.098 |
 STR | 31 (31.6) | 30 (36.1) | 18 (26.5) | 37 (38.5) | 31 (23.0) | 67 (37.4) | 214 (32.5) | 10.845 | 0.055 |
 MDR | 40 (40.8) | 46 (55.4) | 33 (48.5) | 45 (46.9) | 48 (35.6) | 86 (48.0) | 298 (45.2) | 10.328 | 0.066 |
 Any second-line drug resistance | 29 (29.6) | 36 (43.4) | 27 (39.7) | 35 (36.5) | 35 (25.9) | 70 (39.1) | 232 (35.2) | 10.741 | 0.057 |
 CPM | 1 (1.0) | 2 (2.4) | 3 (4.4) | 4 (4.2) | 3 (2.2) | 14 (7.8) | 27 (4.1) | 10.541 | 0.061 |
 KAR | 4 (4.1) | 4 (4.8) | 7 (10.3) | 9 (9.4) | 5 (3.7) | 8 (4.5) | 37 (5.6) | 6.544 | 0.257 |
 OFX | 28 (28.6) | 34 (41.0) | 26 (38.2) | 34 (35.4) | 33 (24.4) | 59 (33.0) | 214 (32.5) | 8.806 | 0.117 |
 PTO | 1 (1.0) | 1 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 16 (8.9) | 18 (2.7) | 35.332 | < 0.001 |
 XDR | 4 (4.1) | 2 (2.4) | 5 (7.4) | 9 (9.4) | 4 (3.0) | 6 (3.4) | 30 (4.6) | 7.670 | 0.175 |